NF-κB–dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity
Ghita Ghislat, Ammar Sabir Cheema, Elodie Baudoin, Christophe Verthuy, Pedro J. Ballester, Karine Crozat, Noudjoud Attaf, Chuang Dong, Pierre Milpied, Bernard MALISSEN, Nathalie Auphan‐Anezin, Thien‐Phong Vu Manh, Marc Dalod, Toby Lawrence
Abstract
T cells. Last, we demonstrate the relevance of these findings to patients with melanoma, showing that activation of the NF-κB/IRF1 axis in association with cDC1s is linked with improved clinical outcome. The NF-κB/IRF1 axis in cDC1s may therefore represent an important focal point for the development of new diagnostic and therapeutic approaches to improve cancer immunotherapy.
Topics & Concepts
BiologyCancer immunotherapyCell biologyImmunotherapyIRF1Signal transductionCancer researchCytotoxic T cellNF-κBImmune systemImmunologyTranscription factorGeneBiochemistryIn vitroImmunotherapy and Immune ResponsesT-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers